Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. (Q46971502)

27 December 2017

title

Enhancement of dendritic cell-tumor fusion vaccine potency by indoleamine-pyrrole 2,3-dioxygenase inhibitor, 1-MT. (English)

1 reference

27 December 2017

author name string

Xueling Ou

1

1 reference

27 December 2017

Shaohui Cai

2

1 reference

27 December 2017

Peng Liu

3

1 reference

27 December 2017

Jun Zeng

4

1 reference

27 December 2017

Yuwen He

5

1 reference

27 December 2017

Xinyao Wu

6

1 reference

27 December 2017

Jun Du

7

1 reference

27 December 2017

publication date

2 October 2007

1 reference

27 December 2017

Journal of Cancer Research and Clinical Oncology

published in

1 reference

27 December 2017

volume

134

1 reference

27 December 2017

issue

5

1 reference

27 December 2017

page(s)

525-533

1 reference

27 December 2017

https://scigraph.springernature.com/pub.10.1007/s00432-007-0315-9

exact match

0 references

cites work

Cyclooxygenase-2 inhibitor enhances the efficacy of a breast cancer vaccine: role of IDO.

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Identification of new antigenic peptide presented by HLA-Cw7 and encoded by several MAGE genes using dendritic cells transduced with lentiviruses

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Inhibition of experimental asthma by indoleamine 2,3-dioxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Tumor-derived TGF-beta reduces the efficacy of dendritic cell/tumor fusion vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Cells expressing indoleamine 2,3-dioxygenase inhibit T cell responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Cutting edge: CpG oligonucleotides induce splenic CD19+ dendritic cells to acquire potent indoleamine 2,3-dioxygenase-dependent T cell regulatory functions via IFN Type 1 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Induction of efficient antitumor immunity using dendritic cells activated by recombinant Sendai virus and its modulation by exogenous IFN-beta gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Rapid and strong human CD8+ T cell responses to vaccination with peptide, IFA, and CpG oligodeoxynucleotide 7909.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00432-007-0315-9

Relationship between interferon-gamma, indoleamine 2,3-dioxygenase, and tryptophan catabolism

21 January 2018

1 reference

12 December 2020

The host-tumor immune conflict: from immunosuppression to resistance and destruction

1 reference

12 December 2020

Modulation of tryptophan catabolism by regulatory T cells.

1 reference

12 December 2020

Evidence for a tumoral immune resistance mechanism based on tryptophan degradation by indoleamine 2,3-dioxygenase

1 reference

12 December 2020

Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy.

1 reference

12 December 2020

Prevention of allogeneic fetal rejection by tryptophan catabolism

1 reference

12 December 2020

T cell proliferation is blocked by indoleamine 2,3-dioxygenase.

1 reference

12 December 2020

Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines

1 reference

12 December 2020

Dendritic cells pulsed with HER-2/neu-derived peptides can induce specific T-cell responses in patients with gastric cancer

1 reference

12 December 2020

Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells

1 reference

12 December 2020

Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy.

1 reference

12 December 2020

Halted trial renews questions about cancer vaccines

1 reference

12 December 2020

Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy

1 reference

12 December 2020

The therapeutic potential of 4-1BB (CD137) in cancer.

1 reference

12 December 2020

T cell-dependent antitumor immunity mediated by secondary lymphoid tissue chemokine: augmentation of dendritic cell-based immunotherapy.

1 reference

12 December 2020

Cancer immunotherapy: moving beyond current vaccines

1 reference

12 December 2020

Dendritic cell based antitumor vaccination: impact of functional indoleamine 2,3-dioxygenase expression.

1 reference

12 December 2020

Binding activity of H-Ras is necessary for in vivo inhibition of ASK1 activity

1 reference

12 December 2020

Immune suppression in the tumor microenvironment

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation

1 reference

12 December 2020

Dendritic cells presenting tumor antigen.

1 reference

12 December 2020

IDO and tolerance to tumors

1 reference

12 December 2020

Therapeutic efficacy of MUC1-specific cytotoxic T lymphocytes and CD137 co-stimulation in a spontaneous breast cancer model.

1 reference

12 December 2020

4-1BB-mediated immunotherapy of rheumatoid arthritis.

1 reference

12 December 2020

Tryptophan degradation in mice initiated by indoleamine 2,3-dioxygenase

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase in cancer: targeting pathological immune tolerance with small-molecule inhibitors.

1 reference

12 December 2020

Enhanced immune response to the melanoma antigen gp100 using recombinant adenovirus-transduced dendritic cells

1 reference

12 December 2020

Interleukin-10-treated human dendritic cells induce a melanoma-antigen-specific anergy in CD8(+) T cells resulting in a failure to lyse tumor cells.

1 reference

12 December 2020

Dendritic cell/myeloma hybrid vaccine

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

1 reference

12 December 2020

Dendritic cells and the control of immunity

1 reference

12 December 2020

Immunology at the maternal-fetal interface: lessons for T cell tolerance and suppression

1 reference

12 December 2020

Inhibition of indoleamine 2,3-dioxygenase augments trinitrobenzene sulfonic acid colitis in mice

1 reference

12 December 2020

Immunological properties and vaccine efficacy of murine dendritic cells simultaneously expressing melanoma-associated antigen and interleukin-12.

1 reference

12 December 2020

Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells

1 reference

12 December 2020

Increasing tumor antigen expression overcomes "ignorance" to solid tumors via crosspresentation by bone marrow-derived stromal cells

1 reference

12 December 2020

Induction of autologous CD4- and CD8-mediated T-cell responses against acute lymphocytic leukemia cell line using apoptotic tumor cell-loaded dendritic cells

1 reference

12 December 2020

Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation

1 reference

12 December 2020

10.1007/S00432-007-0315-9

Identifiers

DOI

1 reference

27 December 2017

1 reference

27 December 2017